GSA CAPITAL PARTNERS LLP

Position in SUPN — Supernus Pharmaceuticals, Inc.

CIK 1362033 LONDON, X0

Position in SUPN

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$545,639

+$133,030 QoQ

Shares Held

10,556

+27.2% QoQ

Ownership

0.018%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2022

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $10,107,066 across 16 Drug Manufacturers - Specialty & Generic names. SUPN ranks #7 (5.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	IRWD	Ironwood Pharmaceuticals Inc	654,445	$2,297,101
2	LQDA	Liquidia Corp	35,406	$1,336,222
3	VTRS	Viatris Inc	89,952	$1,215,251
4	NBIX	Neurocrine Biosciences Inc	6,688	$881,077
5	RGC	Regencell Bioscience Holdings Ltd	31,569	$802,799
6	XERS	Xeris Biopharma Holdings, Inc.	101,438	$588,340
7	SUPN	Supernus Pharmaceuticals, Inc. This page	10,556	$545,639
8	KNSA	Kiniksa Pharmaceuticals International, plc	11,257	$542,024

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$545,639	10,556	+27.2%	Shares	Sole	2026-05-08
2025-12-31	$412,609	8,302	-76.5%	Shares	Sole	2026-02-06
2025-06-30	$1,112,120	35,283	-61.0%	Shares	Sole	2025-07-22
2025-03-31	$2,965,119	90,538	+375.0%	Shares	Sole	2025-05-08
2024-12-31	$689,209	19,060	-69.7%	Shares	Sole	2025-02-07
2024-09-30	$1,959,070	62,831	+218.2%	Shares	Sole	2024-11-05
2024-06-30	$528,178	19,745	+170.7%	Shares	Sole	2024-08-15
2024-03-31	$248,798	7,294	-12.4%	Shares	Sole	2024-05-03
2023-12-31	$240,925	8,325	+14.2%	Shares	Sole	2024-02-16
2023-09-30	$200,902	7,287	-55.6%	Shares	Sole	2023-11-15
2022-12-31	$584,773	16,394	+63.6%	Shares	Sole	2023-02-13
2022-03-31	$323,943	10,023	—	Shares	Sole	2022-05-11
No filing history on record for this holder in this stock.